Abstracts tagged "ANCA"

Abstract Number: 1535 • 2012 ACR/ARHP Annual Meeting
Genetic Background of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Japanese Population: Association of STAT4 with Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Positive Vasculitis
Aya Kawasaki¹, Naoya Inoue¹, Chihiro Ajimi¹, Ikue Ito¹, Ken-ei Sada², Shigeto Kobayashi³, Hidehiro Yamada⁴, Hiroshi Furukawa⁵, Makoto Tomita⁶, Takayuki Sumida⁷, Shigeto Tohma⁸, Nobuyuki Miyasaka⁹, Shoichi Ozaki⁴, Hiroshi Hashimoto¹⁰, Hiroshi Makino², Masayoshi Harigai¹¹ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Medicine and Clinical Science, Okayama University, Okayama, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University, Kawasaki, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁶Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ⁷Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁸Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan, ⁹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁰Juntendo University School of Medicine, Tokyo, Japan, ¹¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: In antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), geographic difference in the type of vasculitis is well known. While granulomatosis with polyangiitis (GPA) is the…
Abstract Number: 2565 • 2012 ACR/ARHP Annual Meeting
Prevalence of Anti-Neutrophil Cytoplasmic Antibodies in Infective Endocarditis: An Analysis of 109 Cases
Alfred Mahr¹, Frédéric Batteux², Sarah Tubiana³, Michel Wolff⁴, Claire Goulvestre², Thomas Papo⁵, François Vrtovsnik⁶, Isabelle Klein⁷, Bernard Iung⁸ and Xavier Duval⁹, ¹Internal Medicine, Hospital Saint-Louis, Paris, France, ²Laboratoire d'Immunologie, Hospital Cochin, Paris, France, ³Clinical Investigation, Hospital Bichat, Paris, France, ⁴Intensive Care Unit, Hospital Bichat, Paris, France, ⁵Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ⁶Nephrology, Hospital Bichat, Paris, France, ⁷Radiology, University Paris-7, APHP, Bichat Hospital, Paris, France, ⁸Cardiology, Hospital Bichat, Paris, France, ⁹Infectious Diseases, Hospital Bichat, Paris, France
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCAs), particularly those directed against proteinase 3 (anti-PR3) or myeloperoxydase (anti-MPO), are considered a highly specific hallmark of ANCA-associated vasculitis. Thus,…
Abstract Number: 1536 • 2012 ACR/ARHP Annual Meeting
Clinical Features of Patients with Anti-Neutrophil Cytoplasmic Autoantibodies Targeting Native Myeloperoxidase Antigen
Yuji Yamanishi¹, Toshiko Ito-Ihara², Shigeto Kobayashi³, Peter Y. Shane⁴, Gary S. Firestein⁵, Hiroshi Hashimoto⁶ and Kazuo Suzuki⁷, ¹Division of Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan, ²Department of Clinical Innovative Medicine, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁶Juntendo Tokyo Koto Geriatric Center, Tokyo, Japan, ⁷National Institute of Infectious Diseases, Tokyo, Japan
Background/Purpose: ANCA is a useful diagnostic marker in systemic vasculitic disorders with small-vessel involvement, but depending on the particular test used the myeloperoxidase (MPO)-ANCA results…
Abstract Number: 2393 • 2012 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins
Alexandre Wagner S. de Souza¹, Karina de Leeuw², Johanna Westra², Andries J. Smit³, Anne Marijn van der Graaf², Hans L. A. Nienhuis¹, Johan Bijzet², Pieter C. Limburg⁴, Coen A. Stegeman⁵, Marc Bijl⁶ and Cees G.M. Kallenberg², ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Vascular Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Department of Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁵Nephrology, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, Martini Hospital, Groningen, Netherlands
Background/Purpose: High mobility group box 1 (HMGB1) is a non-histone DNA binding protein that is passively released by dying cells or actively secreted by immunocompetent…
Abstract Number: 860 • 2012 ACR/ARHP Annual Meeting
Interleukin-21, B Cell Activating Factor and Unmethylated CpG Oligodeoxynucleotides Synergize in Promoting Anti-Proteinase 3 Autoantibody Production in Vitro
Nikola Lepse¹, Judith Land², Abraham Rutgers², Cees G.M. Kallenberg², Coen A. Stegeman³, Peter Heeringa¹ and Wayel H. Abdulahad², ¹Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Nephrology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are characterized by the presence of circulating autoantibodies that are often directed against proteinase 3 (PR3). Although the…
Abstract Number: 2379 • 2012 ACR/ARHP Annual Meeting
Successful Treatment of Churg-Strauss Syndrome with Rituximab
Christin Dubrau¹, Fabian Arndt², Wolfgang L. Gross and Frank Moosig⁴, ¹Departement of Rheumatology and Clinical Immunology, University Hospital Schleswig-Holstein, Campus Luebeck and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, ²Departement of rheumatology and clinical immunology, University Hospital Schleswig Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, ³Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany
Background/Purpose: Rituximab has recently been shown to be equipotent to cyclophosphamide for induction of remission in generalized ANCA-associated vasculitis. A substantial number of observational pro-…
Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting
Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients
Pierre Charles¹, Antoine Néel², Nathalie Tieulié³, Arnaud Hot⁴, Grégory Pugnet⁵, Olivier Decaux⁶, Isabelle Marie⁷, Mehdi Khellaf⁸, Jean-Emmanuel Kahn⁹, Alexandre Karras¹⁰, Jean-Marc Ziza¹¹, Christophe Deligny¹², Colas Tchérakian¹³ and Loic Guillevin¹⁴, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²Internal Medicine, Nantes University Hospital, Nantes, France, ³CHU Nice, Nice, France, ⁴Internal Medicine, Edouard Herriot University Hospital, Lyon, France, ⁵Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ⁶Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁷Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, ⁸Internal Medicine, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ⁹Internal Medicine, Foch Hospital, Suresnes, France, ¹⁰Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ¹¹Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹²Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ¹³Service de pneumologie, hôpital Foch, Suresnes, France, ¹⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…
Abstract Number: 2700 • 2012 ACR/ARHP Annual Meeting
A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody Testing
Tarun S. Sharma¹, Vikash Sinha², Vino Unson², Saurav Acharya³, Sahar Mohammadi² and Amer Syed², ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Internal Medicine, Mount.Sinai School of Medicine-Jersey City Medical Center, Jersey City, NJ, ³Internal Medicine, Jersey City Medical Center-Barnabas Health, Jersey City, NJ
A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody TestingBackground/Purpose: Anti Neutrophil Cytoplasmic Antibody (ANCA) test is an Indirect Immunoflorescence test used as an…
Abstract Number: 1774 • 2012 ACR/ARHP Annual Meeting
Identification of Target Antigens of Anti-Endothelial Cell Antibodies in Patients with ANCA-Associated Systemic Vasculitis: A Proteomic Approach
Alexis Régent¹, Hanadi Dib², Guillaume Bussone¹, Mathieu C. Tamby¹, Nicolas Tamas², Christian Federici³, Cédric Broussard³, Loic Guillevin⁴ and Luc Mouthon¹, ¹Internal Medicine, Hopital Cochin, Paris, France, ²Université Paris Descartes, Paris, France, ³Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, ⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Anti-endothelial cell antibodies (AECA) are frequently detected in anti-neutrophil cytoplasm antibodies (ANCA)-associated systemic vasculitis (AAV) and are considered to play pathological roles but their…
Abstract Number: 1652 • 2012 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Loic Guillevin¹, Christian Pagnoux², Alexandre Karras³, Chahera Khoutra⁴, Olivier Aumaitre⁵, Pascal Cohen⁶, Francois Maurier⁷, Olivier Decaux⁸, Hélène Desmurs-Clavel⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puechal¹⁴, Pierre-Louis Carron¹⁵, Pierre yves Hatron¹⁶, Nicolas Limal¹⁷, Mohamed Hamidou¹⁸, Maize Ducret¹⁹, Florence Vende²⁰, Elisa Pasqualoni²¹, Bernard Bonnotte²², Philippe Ravaud²³, Luc Mouthon²⁴ and French Vasculitis Study Group (FVSG)²⁵, ¹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ²Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴Pneumology, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ⁵Department of Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹²Internal Medicine, Centre Hospitalier, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Internal Medicine, Hôpital Cochin, Paris, France, ¹⁵Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁶Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, ¹⁷Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁸Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹⁹Department of Internal Medicine, Centre Hospitalier d'Annecy, Annecy, France, ²⁰Nephrology, Hôpital Bicbat, APHP, Paris, France, ²¹Department of Internal Medicine, Hôpital Bicbat, APHP, Paris, France, ²²Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²⁴Internal Medicine, Hopital Cochin, Paris, France, ²⁵Internal Medicine, Hôpital Cochin, Université Paris–Descartes, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission has been achieved with CS and cyclophosphamide (CYC), maintenance therapy usually relies on azathioprine (AZA) or methotrexate. However, 18-…
Abstract Number: 1654 • 2012 ACR/ARHP Annual Meeting
Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial
Eli Miloslavsky¹, Ulrich Specks², John H. Stone³ and RAVE/ITN Research Group⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Bethesda, MD
Primary Endpoint Failure in the Rituximab in ANCA-associated Vasculitis TrialBackground/Purpose: The RAVE trial demonstrated that rituximab (RTX) is non-inferior to cyclophosphamide (CYC) for remission induction…
Abstract Number: 1538 • 2012 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis in Hispanic Americans: An Unrecognized Severity
Ranadeep Mandhadi¹, Fadi Aldaghlawi², Asad Khan², Vajiha Irshad³, Joel A. Block² and Antoine Sreih⁴, ¹Mount Sinai Hospital, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Internal Medicine, Stroger Hospital of Cook County, Chicago, IL, ⁴Medicine/Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: ANCA-associated vasculitis, once a disease thought to predominate in Caucasians, is now increasingly recognized in diverse ethnic populations. However, there has been little systematic…
Abstract Number: 1541 • 2012 ACR/ARHP Annual Meeting
Does Leflunomide Have a Place As Remission Maintenance Therapy in ANCA-Associated Vasculitis? A Bayesian Network Meta-Analysis with Hypothesis Driven Sensitivity Analyses to Adjust for Potential Biases
Glen S. Hazlewood¹, Claudia Metzler², George A. Tomlinson³, Wolfgang L. Gross⁴, Brian M. Feldman⁵, Loic Guillevin⁶ and Christian Pagnoux⁷, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²University of Lubeck, Bad Branstedy, Germany, ³University of Toronto, Toronto, ON, Canada, ⁴Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Internal Medicine, Cochin University Hospital, Paris, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Primary: To determine the relative treatment effects of maintenance therapy in adult patients with ANCA-associated vasculitis who have achieved remission, using a Bayesian network…
Abstract Number: 1542 • 2012 ACR/ARHP Annual Meeting
The Efficacy of Rituximab Vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE Trial Geetha D, Fervenza FC for the RAVE-Itn Research Group
Duvuru Geetha¹ and Fernando Fervenza², ¹Nephrology, Johns Hopkins University, Baltimore, MD, ²Mayo Clinic, Rochester, MN
Background/Purpose: Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANCA associated vasculitis (AAV) but details of outcomes among…
Abstract Number: 1543 • 2012 ACR/ARHP Annual Meeting
Rituximab for ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Trials
Carolina Mejia¹ and Carlos J. Lozada², ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Over the past 40 years, cyclophosphamide/glucocorticoids combination therapy has been the standard regimen for remission induction in ANCA-associated vasculitis.. Although a major advance in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.